Vanda Pharmaceuticals
VNDA
109 hedge funds and large institutions have $538M invested in Vanda Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 43 increasing their positions, 32 reducing their positions, and 19 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
80% more call options, than puts
Call options by funds: $8.52M | Put options by funds: $4.72M
34% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 32
25% more capital invested
Capital invested by funds: $431M → $538M (+$107M)
1% less funds holding
Funds holding: 110 → 109 (-1)
5% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$15.5M |
| 2 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
+$9.71M |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$9.31M |
| 4 |
DM
Deerfield Management
New York
|
+$7.01M |
| 5 |
GTC
Ghost Tree Capital
New York
|
+$3.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$27.5M |
| 2 |
Goldman Sachs
New York
|
-$14.8M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$14.5M |
| 4 |
AC
Armistice Capital
New York
|
-$12.3M |
| 5 |
JG
Jefferies Group
New York
|
-$8.04M |
VNDA Hedge Fund Activity: Q2 2015 in Review
109 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q2 2015, worth a combined $538M — up 25% from $431M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of VNDA and 18 opened new positions — a net loss of 1 holder — while 32 trimmed existing stakes and 43 added.
The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $15.5M. The largest seller was Fidelity Investments, exiting entirely with an estimated $27.5M sold.
- 109 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q2 2015, down from 110 in Q1 2015.
- Funds reported $538M of Vanda Pharmaceuticals stock for Q2 2015, up 25% quarter-over-quarter.
- 18 funds opened new Vanda Pharmaceuticals positions in Q2 2015 and 19 closed out, a net change of -1 holder.
- The largest Vanda Pharmaceuticals buyer in Q2 2015 was Avoro Capital Advisors, an estimated $15.5M added.
- The largest Vanda Pharmaceuticals seller in Q2 2015 was Fidelity Investments, an estimated $27.5M sold.
Based on aggregated 13F filings for Q2 2015.